BR112017021283A2 - comprimido de ribociclib - Google Patents

comprimido de ribociclib

Info

Publication number
BR112017021283A2
BR112017021283A2 BR112017021283A BR112017021283A BR112017021283A2 BR 112017021283 A2 BR112017021283 A2 BR 112017021283A2 BR 112017021283 A BR112017021283 A BR 112017021283A BR 112017021283 A BR112017021283 A BR 112017021283A BR 112017021283 A2 BR112017021283 A2 BR 112017021283A2
Authority
BR
Brazil
Prior art keywords
tablet
ribocyclib
relates
present
coating
Prior art date
Application number
BR112017021283A
Other languages
English (en)
Inventor
Grandeury Arnaud
Gururajan Bindhumadhavan
Costa Rui
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55806565&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112017021283(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR112017021283A2 publication Critical patent/BR112017021283A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

a presente invenção refere-se a comprimido oral de ribociclib incluindo seu(s) sal(ais). uma modalidade da presente invenção refere-se a um comprimido de ribociclib com uma alta carga de fármaco com um perfil de liberação imediata. uma modalidade da presente invenção refere-se a comprimido revestido de ribociclib. uma outra modalidade da presente invenção refere-se a comprimido revestido de ribociclib onde o revestimento é um revestimento de barreira de umidade avançada (por exemplo, revestimento opadry® amb ii onde o revestimento é à base de pva).
BR112017021283A 2015-04-16 2016-04-14 comprimido de ribociclib BR112017021283A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562148240P 2015-04-16 2015-04-16
PCT/IB2016/052136 WO2016166703A1 (en) 2015-04-16 2016-04-14 Ribociclib tablet

Publications (1)

Publication Number Publication Date
BR112017021283A2 true BR112017021283A2 (pt) 2018-06-26

Family

ID=55806565

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017021283A BR112017021283A2 (pt) 2015-04-16 2016-04-14 comprimido de ribociclib

Country Status (29)

Country Link
US (3) US10799506B2 (pt)
EP (2) EP4197530A1 (pt)
JP (1) JP2018514523A (pt)
KR (1) KR20170137101A (pt)
CN (2) CN115554257A (pt)
AR (1) AR104257A1 (pt)
AU (4) AU2016248017A1 (pt)
BR (1) BR112017021283A2 (pt)
CA (1) CA2982425C (pt)
CL (1) CL2017002593A1 (pt)
CO (1) CO2017010510A2 (pt)
DK (1) DK3283058T3 (pt)
EA (1) EA201792290A1 (pt)
EC (1) ECSP17075052A (pt)
ES (1) ES2938261T3 (pt)
FI (1) FI3283058T3 (pt)
HR (1) HRP20230053T1 (pt)
HU (1) HUE061213T2 (pt)
IL (1) IL254818A0 (pt)
MX (1) MX2017013350A (pt)
PE (1) PE20180035A1 (pt)
PH (1) PH12017501820A1 (pt)
PL (1) PL3283058T3 (pt)
PT (1) PT3283058T (pt)
SG (1) SG11201708084PA (pt)
SI (1) SI3283058T1 (pt)
TN (1) TN2017000422A1 (pt)
TW (1) TW201642864A (pt)
WO (1) WO2016166703A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3283058T3 (pl) * 2015-04-16 2023-03-20 Novartis Ag Tabletka rybocyklibu
CA3048036A1 (en) 2018-07-02 2020-01-02 Apotex Inc Novel crystalline form of ribociclib succinate
US20230310327A1 (en) * 2020-08-03 2023-10-05 Natco Pharma Limited Pharmaceutical compositions comprising ribociclib
WO2022162122A1 (en) 2021-01-29 2022-08-04 Biotx.Ai Gmbh Genetically verified netosis inhibitor for use in the treatment of a sars-cov2 infection
TW202329977A (zh) 2022-01-25 2023-08-01 瑞士商諾華公司 瑞博西尼藥物組成物
WO2024049926A1 (en) 2022-08-31 2024-03-07 Arvinas Operations, Inc. Dosage regimens of estrogen receptor degraders

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5428812A (en) * 1977-08-09 1979-03-03 Yoshitomi Pharmaceut Ind Ltd Preparation of coated tablet
GB9414045D0 (en) 1994-07-12 1994-08-31 Berwind Pharma Service Moisture barrier film coating composition, method, and coated form
CZ297271B6 (cs) * 1994-07-12 2006-10-11 Bpsi Holdings, Inc. Suchá povlaková hmota pro výrobu filmu zabranujícímu prístupu vlhkosti, zpusob a tvorba povlaku
US6448323B1 (en) * 1999-07-09 2002-09-10 Bpsi Holdings, Inc. Film coatings and film coating compositions based on polyvinyl alcohol
PL2331547T3 (pl) 2008-08-22 2015-01-30 Novartis Ag Związki pirolopirymidynowe jako inhibitory CDK
US20120115878A1 (en) 2010-11-10 2012-05-10 John Vincent Calienni Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof
SI2673266T1 (sl) * 2011-02-11 2016-11-30 Wista Laboratories Ltd. Fenotiazin diaminijeve soli in njihova uporaba
DK2872482T3 (da) * 2012-07-13 2020-09-21 Oncternal Therapeutics Inc En fremgangsmåde til behandling af brystkræft med selektiv androgenreceptormodulator (sarm)
EP3251673A1 (en) 2012-12-13 2017-12-06 IP Gesellschaft für Management mbH Combination therapy comprising a cdk4/6 inhibitor and a pi3k inhibitor for use in the treatment of cancer
WO2014097125A1 (en) * 2012-12-20 2014-06-26 Novartis Ag Pharmaceutical combination comprising binimetinib
AU2014233805B2 (en) * 2013-03-21 2018-10-18 Array Biopharma Inc. Combination therapy comprising a B-Raf inhibitor and a second inhibitor
EP2810644A1 (en) * 2013-06-06 2014-12-10 Ferrer Internacional, S.A. Oral formulation for the treatment of cardiovascular diseases
PL3283058T3 (pl) * 2015-04-16 2023-03-20 Novartis Ag Tabletka rybocyklibu
CN109953966A (zh) * 2017-12-26 2019-07-02 天津耀辰实业发展有限公司 一种含有瑞博西尼的药物组合物及其制备方法
JP7347388B2 (ja) 2020-09-25 2023-09-20 信越化学工業株式会社 紫外線硬化型有機変性シリコーン組成物および硬化物

Also Published As

Publication number Publication date
KR20170137101A (ko) 2017-12-12
FI3283058T3 (fi) 2023-03-01
CL2017002593A1 (es) 2018-05-18
ES2938261T3 (es) 2023-04-05
TW201642864A (zh) 2016-12-16
PL3283058T3 (pl) 2023-03-20
SI3283058T1 (sl) 2023-03-31
US20200390771A1 (en) 2020-12-17
CN115554257A (zh) 2023-01-03
JP2018514523A (ja) 2018-06-07
AU2022215155A1 (en) 2022-09-01
EP4197530A1 (en) 2023-06-21
IL254818A0 (en) 2017-12-31
AU2016248017A1 (en) 2017-10-19
US10799506B2 (en) 2020-10-13
US20230104792A1 (en) 2023-04-06
EP3283058B1 (en) 2022-11-16
PT3283058T (pt) 2023-02-03
MX2017013350A (es) 2018-01-25
US20180071292A1 (en) 2018-03-15
SG11201708084PA (en) 2017-10-30
CN107530292A (zh) 2018-01-02
CO2017010510A2 (es) 2018-03-20
AR104257A1 (es) 2017-07-05
CN107530292B (zh) 2022-11-01
CA2982425C (en) 2023-10-31
PE20180035A1 (es) 2018-01-09
EP3283058A1 (en) 2018-02-21
HUE061213T2 (hu) 2023-05-28
AU2019201929B2 (en) 2020-07-09
AU2020250190A1 (en) 2020-11-05
ECSP17075052A (es) 2018-02-28
EA201792290A1 (ru) 2018-02-28
WO2016166703A1 (en) 2016-10-20
CA2982425A1 (en) 2016-10-20
AU2019201929A1 (en) 2019-04-11
HRP20230053T1 (hr) 2023-03-03
TN2017000422A1 (en) 2019-01-16
DK3283058T3 (da) 2023-02-13
PH12017501820A1 (en) 2018-04-23

Similar Documents

Publication Publication Date Title
BR112017021283A2 (pt) comprimido de ribociclib
CY1124336T1 (el) Φαρμακευτικες συνθεσεις που περιλαμβανουν φουμαρικο διμεθυλιο
BR112016024631A2 (pt) cápsulas antimicrobianas para conectores médicos
BR112016028288A2 (pt) ?composto, composição farmacêutica, métodos para tratamento de um indivíduo com uma doença ou condição e para inibir a quinase, e, uso de um composto?
BR112018013218A2 (pt) derivado de acrilanilida, método de preparação e aplicação do mesmo na farmácia
BR112018013462A2 (pt) métodos de fabricação de aditivo para adesivos e artigos adesivos
BR112015032693A2 (pt) inibidores de bromodomínio
BR112018007395A2 (pt) 2,4-di-hidróxi-nicotinamidas como agonistas de apj
DK3513809T3 (da) Medicinsk sammensætning, som omfatter tivozanib
CL2016001587A1 (es) Derivado basado en 1,2-naftoquinona y método de preparación del mismo.
BR112017012406A2 (pt) formulação com relação fixa de insulina glargina/lixisenatida
EP3607679A4 (en) OPTICAL IMPLEMENTATION OF A BUTLER MATRIX
BR112017025427A2 (pt) composição farmacêutica oral
BR112019001386A2 (pt) composição clareadora e de revestimento dos dentes e composição
BR112015024703A2 (pt) formulação farmacêutica, método de tratamento e/ou prevenção de restenose e kit para o tratamento e/ou prevenção de restenose
DK4056557T3 (da) Benzazepinderivater nyttige som medikamenter
EP3681887A4 (en) EPOXYEICOSATRIENOIC ACID (TEE) ANALOGUES TARGETING THE KIDNEYS
EP3245189A4 (en) Modulators of ca2+ release-activated ca2+ (crac) channels and pharmaceutical uses thereof.
BR112019023664A8 (pt) Forma de dosagem em pastilha
BR112016028083A2 (pt) Composição oral farmacêutica de isotretinoina e seu processo de preparação
BR112017021961A2 (pt) produto de confeitaria, embalagem e processo para a fabricação de um produto de confeitaria
DK3285715T3 (da) Medikamentdoseringspilleudskubningsmekanisme
BR112017018630A2 (pt) componente prendedor macho antienroscamento falso.
EP3705122A4 (en) DELAYED RELEASE MEDICAL COMPOSITION
BR112017001963A2 (pt) composição farmacêutica oral, seu processo de preparação e método de tratamento

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]